Pharma BD Deal Intelligence
Novo Holdings acquired Catalent for $11B (via parent) for Wegovy/Ozempic manufacturing.
Novo Nordisk 6-K covering the $11B acquisition of three Catalent fill-finish sites from Novo Holdings.
Novo Holdings completed its acquisition of Catalent in an all-cash transaction with a total enterprise value of ~$16.5B; holders received $63.50/share. Novo…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Novo Holdings acquired Catalent in an all-cash deal with a total enterprise value of approximately $16.5 billion ($63.50/share), closed December 18, 2024 after EU Commission unconditional approval (Dec 6, 2024) and the FTC declining to challenge. Concurrently, Novo Nordisk acquired three Catalent fill-finish sites (Anagni, Italy; Bloomington, Indiana; Brussels, Belgium) from Novo Holdings for $11 billion to secure and scale GLP-1 fill-finish capacity for Wegovy and Ozempic, expanding Novo Nordisk's fill-finish footprint from 11 to 14 sites.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Novo Holdings A/S / Catalent (manufacturing sites) (this deal) | 2024 | $11.0B | 81 |
| Novo Holdings A/S / Catalent, Inc. | 2016 | $16.5B | 68 |
| Novo Nordisk A/S / Emisphere Technologies | 2020 | $1.4B | 90 |
| Roche Holding AG / Corange Ltd. (Boehringer Mannheim Group) | 1997 | $11.0B | 88 |
| Sanofi SA / Genzyme Corporation | 2011 | $20.1B | 84 |
| AstraZeneca PLC / Bristol-Myers Squibb Company / Amylin diabetes alliance | 2012 | $3.5B | 77 |
| Roche Holding AG / Carmot Therapeutics Inc. | 2023 | $2.7B | 72 |
← Browse all deals · How we score deals
More: 2024 deals · Metabolic deals